Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search How is psoriatic arthritis diagnosed? See related Handbook section PREVIOUS NEXT

< BACK iPROLEPSIS Innovative Federated Learning Approach at IEEE IST 2023 Oct 23, 2023 Enhancing Federated Learning Through Advanced Weight Distribution Analysis IEEE International Conference on Imaging Systems and Techniques (IST) conference served as a platform for presenting iPROLEPSIS research in federated learning, specifically focusing on novel methods for weight aggregation. Title: Federated Learning Aggregation based on Weight Distribution Analysis Abstract: Federated learning has recently been proposed as a solution to the problem of using private or sensitive data for training a central deep model, without exchanging the local data. In federated learning, local models are trained on the client side using the available data, while a server is responsible for aggregating the weights of these models into a global model. However, the traditional weight averaging approach does not take into consideration the importance of the different weights for the performance of a model. To this end, this work proposes a novel federated learning weight aggregation method that estimates the statistical distance of each client's parameters from the Gaussianity, and weighs the contribution of each client to the global model accordingly so that the most significant information is retained and enhanced. To create an accurate global model, a complex weighted averaging of the parameters of clients' models at the layer level is performed, considering as low quality the parameters following the Gaussian distribution. The proposed method can be employed to both convolutional and linear layers and it is based on the notion that parameters following a Gaussian distribution do not significantly affect the output of a model. Experiments with different network architectures and a comparison with a plethora of state-of-the-art approaches on three well-known image classification datasets demonstrate the superiority of the proposed method for federated learning weight aggregation. Read the full publication here: (PDF) Federated Learning Aggregation based on Weight Distribution Analysis ( researchgate.net ) https://ieeexplore.ieee.org/document/10355708 1/1 PREVIOUS NEXT

< BACK Europe Day 2024 May 9, 2024 Celebrating Europe Day with iPROLEPSIS sister projects Happy Europe Day 2024! Today we celebrate unity in diversity, innovation and collaboration across the continent. As projects funded under the same Horizon Europe call topic: "Personalised blueprint of chronic inflammation in health-to-disease transition", we're proud to contribute to the common goals of understanding the risk factors that trigger the transition from health to disease, providing personalised prevention measures and reducing the burden of chronic diseases. Within iPROLEPSIS , we aim to develop a suite of digital health tools designed to detect early transitions to psoriatic arthritis, predict flares for timely intervention, and provide personalised recommendations and interventions for managing the disease. With our unique consortium of 15 partners from 9 countries, we are strengthening international and cross-border collaboration to advance research, technology and health progress in Europe and beyond. Join us in commemorating this special day by exploring the impactful work of our sister projects: GlycanTrigger , ENDOTARGET , IMMEDIATE , miGut-Health , AIDA EU project , PREVALUNG EU , PRAESIIDIUM , CARE-IN-HEALTH , Intercept-T2D , INITIALISE , Halt-RONIN , Together, we're shaping a brighter, more inclusive, and sustainable Europe through groundbreaking research and cross-border connections. Europe Day sister projects .png Europe Day sister projects .png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Showcased at MEDICA 2025 Nov 25, 2025 Project presented by PLUX at an international medical technology trade fair MEDICA 2025 was held in Düsseldorf, Germany, from 17–20 November 2025 and is one of the largest international trade fairs for medical technology and healthcare. iPROLEPSIS was showcased by project partner PLUX at MEDICA 2025, within a shared exhibition space alongside other Portuguese entities. The event offered an opportunity to present the project to industry and healthcare stakeholders and to engage with a broad international audience. MEDICA 2025 2.HEIC MEDICA 2025 1.HEIC MEDICA 2025 2.HEIC 1/2 PREVIOUS NEXT

< BACK iPROLEPSIS 3rd Plenary Meeting Nov 30, 2023 iPROLEPSIS 3rd Plenary Meeting in Rotterdam: 12-13 December 2023 On 12-13 December 2023, iPROLEPSIS partners will meet in Rotterdam for the third plenary meeting. The agenda includes workshops on the PDPID study, digital biomarkers, technical ecosystem development, serious games co-creation, an External Advisory Board session, and more. Stay tuned for updates on our progress! iPROLEPSIS 3rd Plenary meeting (1).png iPROLEPSIS 3rd Plenary meeting (1).png 1/1 PREVIOUS NEXT

< BACK Insights from the Psoriasispatiënten Nederland Information Afternoon Nov 11, 2024 Reflection on the recent information afternoon for patients with psoriasis and psoriatic arthritis hosted by Psoriasispatiënten Nederland On 9 November 2024, in celebration of World Psoriasis Day , Psoriasispatiënten Nederland (Psoriasis Patients Netherlands) hosted an informative event in Nijkerk (the Netherlands). With over 90 attende es, the event was a great success, offering valuable insights and fostering connections among patients, clinicians, and researchers. The event aimed to offer the latest information on psoriasis and psoriatic arthritis while fostering discussions on treatment options and research advancements. A diverse range of expert presentations and interactive sessions enhanced attendees' understanding and contributed to improving patient care. During breaks, participants had the opportunity to visit several information stands and engage with researchers and specialists. iPROLEPSIS was represented by Jolanda Luime ( Erasmus MC ) , who shared insights into the ongoing research project focused on the prevention and early diagnosis of psoriatic arthritis. The event proved to be an insightful and inspiring day, bringing together a diverse group of patients, researchers, and healthcare professionals. The discussions, networking opportunities, and practical sessions contributed to a deeper understanding of psoriatic arthritis and psoriasis, making it a valuable experience for all involved. Read more: Terugblik op de afgelopen informatiemiddag - Psoriasispatiënten Nederland 1/6 PREVIOUS NEXT

< BACK Advancing Digital Health Solutions: Updates on User Research and Co-Creation Nov 20, 2023 Navigating the Development of PDPID-App, Insights from Co-Creation Sessions Updates on user research and co-creation The current status of user research and co-creation involves a dedicated focus on advancing the development of the PDPID-app , scheduled for delivery before January 2023. In early October 2023, Erasmus MC ( EMC) conducted a co-creation session with patient partners to assess the general looks and feel of the User Interface (UI) and identify points to improve the app's usability. In apps used for medical data collection, it is of utmost importance that users know what is expected of them. Furthermore, users should be engaged with the app to a level that minimises missing data. Following this, bi-weekly meetings with patient partners were established to maintain alignment with their ideas. Furthermore, project partner FACULDADE DE MOTRICIDADE HUMANA (FMH-ULISBOA) is developing storyboards for the personalised gaming suite . Three co-creation sessions have been executed: one with healthcare professionals and two with patient partners. Additionally, project partners The Centre for Research and Technology Hellas (CERTH) and FACULDADE DE MOTRICIDADE HUMANA (FMH-ULISBOA) have been working with the clinical partners to identify movements for the video analysis tasks that will be included in the iPROLEPSIS-PDPID study. Multiple hand gestures and full-body movements have been identified for further assessment. Key take-away messages The development of the Digital health tools is still at an early stage. However, several take-away messages from the discussions about the PDPID app are : The general looks and UI of the miPROLEPSIS app have been approved by the patient partners. Even though the PDPID-app is a data-collection app for research purposes, patients find it of utmost importance that they can review their own data entries. Participants indicated that the app needs to improve its’ visual cues of when they need to perform certain activities. Take-away messages from the discussions about personalised gaming suite development: Smart games meant for disease management should be highly tailored to the capabilities of the patients. Gaming is for patients a way of relaxation, any game designed should not incorporate any stressful factors. Patient partners expressed interest in the proposed gaming categories. Future steps Future steps involve initiating a round of user testing for the PDPID version of the miPROLEPSIS app to validate designs with patients not involved in the development process. Subsequently, attention will shift to developing recommendation systems for physical activity and diet, incorporating insights from experts in the field (occupational therapists, physical therapists & nutritionists) and patients themselves. For the personalised gaming suite, the completion of the storyboard is planned for the end of December 2023, when the development of the first prototypes will follow. mIPROLEPSIS app.png mIPROLEPSIS app.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Newsletter No. 11 Mar 10, 2026 Latest News from iPROLEPSIS Welcome to the eleventh edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. iPROLEPSIS project newsletter Issue No. 11_March 2026 .pdf Download PDF • 4.21MB iPROLEPSIS_Newsletter 11.png iPROLEPSIS_Newsletter 11.png 1/1 PREVIOUS NEXT

< BACK World Psoriasis Day 2025: Advancing Prevention and Care Oct 29, 2025 On World Psoriasis Day, iPROLEPSIS highlights ongoing efforts to improve early detection, prevention, and digital support for people living with psoriasis and psoriatic arthritis October 29 marks World Psoriasis Day – a day dedicated to raising awareness of the impact psoriasis has on millions worldwide. For many, the condition goes beyond the skin: up to 30% develop psoriatic arthritis , an inflammatory disease that causes joint pain, stiffness, and fatigue, significantly affecting daily life. This year’s World Psoriasis Day video shares how iPROLEPSIS is working to advance psoriatic arthritis prevention and care. Through clinical studies, digital biomarkers, and co-created digital health tools, the project aims to support early detection , timely monitoring , and personalised care . The ongoing PDPID study is developing and validating predictive models for psoriatic arthritis progression, while the iPROLEPSIS digital ecosystem – including the miPROLEPSIS apps, miDashboard for professionals, and lifestyle interventions – is designed together with patients and clinicians to make technology more supportive of everyday care. Its tools – the miPROLEPSIS and miPROLEPSIS-Lite apps, the miDashboard for professionals, and lifestyle interventions such as serious games and personalised recommendations – are co-created with patients and healthcare providers to ensure they are practical, easy to use, and truly supportive of everyday care. On this World Psoriasis Day, iPROLEPSIS stands with everyone living with psoriasis and psoriatic arthritis. Together with clinical and research partners across Europe, the project continues to work toward earlier detection, prevention, and innovative digital solutions to improve lives. Watch the World Psoriasis Day 2025 video here: https://www.youtube.com/watch?v=FvbTCNH9vMY Screenshot 2025-10-29 083418.png Screenshot 2025-10-29 083418.png 1/1 PREVIOUS NEXT

< BACK User Research and Co-Creation Aug 4, 2023 User Research and Co-Creation are at the core of iPROLEPSIS research process Within iPROLEPSIS , several Digital Health Tools (DHTs) will be developed with the aim to early detect the transition to PsA in PsO patients, to predict flares to allow for early intervention, and to generate personalised recommendations and personalised interventions that help manage the disease. The different DHTs to be developed are: miPROLEPSIS patient app; miPROLEPSIS healthcare practitioner dashboard; biAURA biaural sounds app; Personalised recommendation system; Personalised Gaming Suite (PGS). At iPROLEPSIS , User Research and Co-Creation form the foundation of the research process. Diverse qualitative and quantitative research methods have been employed, including interviews, observations, surveys, and usability testing, to gather data and refine our healthcare solutions. One key approach has been conducting 10 focus groups with Dutch, English, Portuguese, and Greek Psoriatic Arthritis (PsA) patients . Four prominent themes emerged from the focus group discussions: Disease Activity, Coping, Care Experience, Digital Biomarkers. To obtain more specific input from a broader population of PsA patients, a survey was created. The survey consisted of 5 sections dedicated to the following: Demographics & Technological Experience ; miPROLEPSIS Patient App - Content and Appearance; BiAURA App – Preferences; Personalised Serious Gaming Suite – Content and Appearance. Key highlights of the insights gained include: Creation of a Patient Experience Map . Psoriatic Arthritis (PsA) has a great impact on the life of those affected. Emotional wellbeing is highly related to the experienced disease activity fluctuating over time. The patient experience map relates the level of disease activity over time to the level of emotional wellbeing in a graph. The graph was created to empathise with our end users and indicate where our Digital Health Solutions might be able to help with improving their Emotional Wellbeing during various stages of disease. Development of User Personas . Engaging and relatable descriptions of user needs and desires, guiding user-centered design principles for our digital products. User Requirement Updates. Refinement of User Requirements for the Digital Health Tools based on focus group findings, ensuring that our tools meet the real needs of PsA patients. iPROLEPSIS is committed to advancing Psoriatic Arthritis (PsA) management through cutting-edge technology and empathetic design. News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

< BACK Federated AI for Privacy-Preserving Omics Profiling seminar Jun 18, 2024 Advancing Knowledge in Privacy-Preserving AI for Omics Profiling On 18 June 2024, iPROLEPSIS had the opportunity to attend an online seminar organised by our sister project, IMMEDIATE EU Project. The seminar's topic was Federated AI for Privacy-Preserving Omics Profiling, presented by Prof. Dr. Jan Baumbach. Prof. Baumbach is the chair of the Computational Systems Biology lab at the University of Hamburg and leads the Computational BioMedicine group at the University of Southern Denmark. A big thank you to Prof. Baumbach for sharing his expertise and insights on this cutting-edge topic! 1/14 PREVIOUS NEXT

< BACK Ongoing preparation for the iPROLEPSIS-PDPID study Mar 4, 2024 iPROLEPSIS-PDPID Study: Advancing Psoriatic Arthritis through Innovative Digital Biomarkers Patients with Psoriatic arthritis (PsA) experience difficulties in dealing with unpredictable disease activity, which can affect their quality of life. Developing a digital biomarker using a smartphone and smartwatch would allow for unobtrusive monitoring of the disease activity in these patients. Besides, understanding what factors trigger flare would allow for better disease control. The iPROLEPSIS-PDPID study is a multicentre observational cohort study that aims to develop an unobtrusive and affordable digital biomarker capable of detecting changes in disease activity, including flare, and to identify triggers of flare in patients with PsA. The study will be conducted in four countries: the Netherlands, the UK, Portugal and Greece. Ethical approval for initiating the iPROLEPSIS-PDPID study in the Netherlands and the UK has been granted. The OpenClinica platform will be used in the collection and storage of data for the iPROLEPSIS-PDPID study. Future steps include obtaining ethical approvals for Portugal and Greece as well as local approvals from centres participating in each country, and inclusion of patients from each participating country. The miPROLEPSIS phone app , currently under development, will be used in this study. The app will be installed on the patient smartphone and utilised as a data collector, which will be then used for algorithms development and training. The app will measure physical activity, the length of sleep, self-registered flare, and register daily pain, fatigue, sleep and morning stiffness. The Garmin smartwatch Vivoactive 5 device will be used to collect data on physical activity, heart rate, heart rate variability and sleep quality. The collected data from Garmin will be downloaded from the miPROLEPSIS app by Wellics software (developer in the project), which allows extracting, visualising and exporting collected both company-processed data, as well as raw data. 10.png 13.png 14.png 10.png 1/5 PREVIOUS NEXT